Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
European Commission Approves Cilta-Cel for R/R Myeloma After at Least 1 Prior Line of Therapy
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC